Chinese pharmaceutical company Kexing Biopharm (SHA:688136) announced on Wednesday that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed innovative product, GB18.
It comes shortly after the US Food and Drug Administration (FDA) approved the IND application for GB18.
GB18 is an innovative biologic product developed for the treatment of cancer cachexia, a complication with a prevalence up to 40-70% among cancer patients. Currently, no specific biological therapies are available to address the condition, presenting vast market potential.
Last October, a research article of GB18's preclinical study was published in international academic journal mAbs. The study demonstrated that GB18 effectively alleviated weight loss in cancer cachexia models, demonstrating superior weight recovery and improved muscle fibres in both quantity and size compared to the comparator.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval